May 27, 2025 · 21m · a16z
7 More Healthy Years: What We Can Learn from Super Agers
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this episode of The a16z Podcast, Dr. Eric Topol joins host Vijay Pande to discuss evidence-based strategies for extending human healthspan and preventing major age-related diseases. Dr. Topol outlines how multi-omics, artificial intelligence, organ-specific biological clocks, GLP-1 therapeutics, and targeted lifestyle modifications can shift medicine from reactive sick care to proactive prevention.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. How this is scored →
The host as informed peer 3.4 Guest teaching 5.3 Guest disagreement 1.3 The host pushing back 0.6
speaking balance: gold is the host, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 19:34 Calling institutional screening 'ingrained in stupidity'
Dr. Topol strongly attacks standard medical practice, stating that current mass cancer screening protocols are ingrained in stupidity rather than using intelligent risk stratification.
Hardest push from the host ▶ 13:48 Challenging GLP-1 dependency and muscle retentionThe host raises concerns regarding muscle loss and rebound weight gain upon stopping GLP-1 drugs, pushing Dr. Topol to address mitigation strategies like strength training.
Biggest teaching moment ▶ 16:30 Explaining proteomic profiling and non-linear aging burstsDr. Topol delivers a technical masterclass on Somalogic and Olink plasma protein measurements, explaining that aging occurs in three distinct physiological bursts rather than a linear slope.
The host holds their own ▶ 8:46 Host outlines machine learning prediction mechanismThe host articulates a specific AI evaluation architecture using temporal data masking to predict future health trajectories, earning explicit agreement and praise from Dr. Topol.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The host as informed peer | Guest teaching | Guest disagreement | The host pushing back | Why |
|---|---|---|---|---|---|---|
| Trailer and Episode Highlights: Healthcare in Crisis | 2 | 4 | 1 | 0 | The host sets up the podcast background and asks Dr. Topol to explain why he wrote Super Agers. Dr. Topol provides context from his Welderly study, a 98-year-old outlier patient, and incoming patient demand for longevity prescriptions. | |
| Reversing Aging vs. Disease Prevention | 3 | 5 | 1 | 0 | The host asks about the state of U.S. healthcare. Dr. Topol distinguishes between reversing aging and preventing the 'big three' age-related diseases, educating the host on disease incubation periods and lifestyle prevention statistics. | |
| Dimensions of Health: AI, Omics, and Cell Therapies | 3 | 6 | 1 | 0 | Dr. Topol walks through the five dimensions of health, detailing multimodal AI, omics, cell therapies, and mRNA cancer vaccines. The host asks for specific examples and agrees with brief confirmatory commentary. | |
| 'Lifestyle Plus' and AI-Driven Risk Trajectories | 5 | 4 | 0 | 0 | The host demonstrates domain expertise by proposing an AI temporal masking method to predict trajectory risks from historical health records. Dr. Topol strongly validates the host's insight and illustrates it with biomarker examples like P-Tau 217. | |
| Defining Healthspan: Staying Cognitively and Physically Intact | 4 | 6 | 1 | 2 | Dr. Topol explains the revolutionary impact of GLP-1 drugs beyond obesity. The host offers gentle pushback regarding muscle loss and post-drug weight rebound, leading Dr. Topol to clarify strength training data and drug developer acquisitions. | |
| Organ-Specific Clocks and Proteomic Profiling | 3 | 6 | 0 | 0 | Dr. Topol explains organ-specific molecular clocks developed at Stanford and plasma proteomic profiling. The host offers brief technical observations on tracking risk non-binarily along a gradient. | |
| Overcoming Skepticism and Reforming Mass Screening | 4 | 6 | 5 | 2 | Dr. Topol aggressively criticizes mass screening practices as 'ingrained in stupidity' and criticizes ineffective FDA-approved Alzheimer's drugs. The host connects the critique to statistical reasoning by suggesting Bayes' rule and priors. |
Statements from this episode (24)
Topol: Longevity requires preventing major diseases, not reversing aging
“We have a path to prevention. It isn't reversing aging. It's just preventing the age-related morbidities of the big three.”
Topol: Risk-partitioned care can add seven healthy years to life
“There should be a reboot new standard of care based on intelligent partitioning of risk. Seven years more of healthspan free of the major three diseases.”
Scripps study finds little genomic explanation for healthy aging to 87
“We had done a big study we called the Welderly, where we basically found very little in the genomes of people who had gone to the age of 87 on average with never having had an age-related disease.”
Topol: Age reversal therapies like senolytics remain unproven in humans
“Where you get reversing of aging, so you keep people healthier body-wide, and that's where we see all this remarkable investments in companies like Altos and with reprogramming, Senolytics, and a long list. But they're really focused on a monumental task, whic…”
Topol: Major age-related diseases incubate for 20 years before symptoms
“It takes 20 years to get these diseases, with rare exception. You know, heart disease, almost all cancers, and neurodegenerative, they are incubating for a very long time.”
Topol: Lifestyle changes can prevent up to 90% of cardiovascular disease
“They, ah, are preventable variably, so cardiovascular, 80 and 90% from lifestyle and related factors, modifiable factors, like your LDL cholesterol, that kind of thing.”
Topol: Lifestyle factors can prevent 50% of cancer and neurodegenerative diseases
“And cancer and neurodegenerative, just from what we know today with lifestyle factors, we're about half that can be prevented.”
Topol: AI is the most critical dimension of modern healthcare
“So the first most important one is AI, because you need that to pull all this other data we're going to talk about together.”
Topol: Comprehensive proteomic panels are now available inexpensively
“So the omics, it includes not just gene sequence or arrays, but it has all the proteins, all the proteomic panels, That we can get, which we never could get before, inexpensively.”
Topol: B-cell depletion resets the immune system to cure autoimmune diseases
“In the last couple of years, we've seen Unprecedented cures. We never had anything. Lupus. Progressive systemic sclerosis. Even cases of multiple sclerosis. Dermatomyositis. So, basically, it's depletion of all the B cells, and when they come back, they have f…”
Topol: Personalized vaccines are curing pancreatic and kidney cancers
“So vaccines now are capable Of cures of pancreatic cancer, kidney cancer, with these personalized vaccines using the proteins of the person's tumor.”
Topol: Immune system therapies will eventually eliminate cancer deaths
“And so, you know, whether it's antibody drug conjugates, a tumor infiltrating lymphocytes, and all these different ways, it's hard to imagine that in the future, we're gonna lose people with cancer, Because of being able to bring your immune system to the high…”
Topol: Lifestyle alone cannot prevent major age-related diseases
“So if each of us did, pulled out all the stops for the lifestyle factors, which is a long list, that will help. But it's not going to be only lifestyle factors that are the ways to prevent the big three age-related diseases.”
Topol: AI biomarker models can predict Alzheimer's onset decades early
“For example, with Alzheimer's, you get a P-Tau, two 17. It's modifiable by lifestyle. You check it again in, you know, six months or a year. Now you have two data points, and you can say, you know, with all the other data that's available, when you're gonna se…”
Topol: GLP-1s are the most momentous drug class in medical history
“It's the most momentous drug class in medical history.”
Topol: A large proportion of the population will take oral GLP-1s
“It wouldn't be surprising to me that now with pills that are remarkably effective to substitute for injections that can be much less expensively. That a large proportion of the population would be taking one of these drugs, or even their successors, that is, t…”
Scripps will run a GLP-1 trial for non-overweight long COVID patients
“We're gonna be doing a long COVID trial in people who are not overweight.”
Topol: At least half of patients regain weight after stopping GLP-1s
“We don't have encouraging data at the moment, because at least half of people gain weight back when they stop.”
Topol: P-tau protein testing provides 20-year warning for cognitive impairment
“We can also look at specific proteins, like, for example, For the brain, p-tau- . And what's amazing about that protein, which we can get now, and it's not that expensive, but that in itself gives us over a twenty-year warning about mild cognitive impairment.”
Topol: Lifestyle modifications can reduce p-tau protein levels up to 80%
“It's modifiable by exercise and lifestyle. We've seen people in studies that drop more than 50%, even up to 80%.”
Topol: FDA-approved Alzheimer's drugs do not work and are very risky
“The Alzheimer's drugs, which don't really work, and they're very risky”